Perkins Coie Named Generic Hatch-Waxman Firm of the Year by LMG Life Sciences

SEATTLE (October 5, 2021)—Perkins Coie is pleased to announce that the firm has been recognized as Hatch-Waxman Litigation Firm of the Year – Generic by the LMG Life Sciences Americas Awards for the second year in a row. The recipients of the LMG Life Sciences Awards—an annual ranking of leading law firms and lawyers specializing in the industry—are determined through a research process involving practitioner submissions and interviews, client feedback, and independent research.

The firm's intellectual property (IP) attorneys represent clients across the full range of life sciences technologies, including biotechnology, pharmaceuticals (branded and generic), biologics, biosimilars, chemistry, diagnostics, medical devices, and digital health. Several IP attorneys have advanced degrees in molecular biology, chemistry, and biophysics, while others actively participate on boards of directors for various life sciences organizations, keeping them at the forefront of industry trends.